Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback